TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Cytokine ratio IFN/IL-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: prevalence of oral leukoplakia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: size of oral leukoplakia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: histologic severity of oral leukoplakia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Eyes With UCDVA of 20/20 or Better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: morphine and morphine equivalent consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Modified Rankin scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of Indigo Carmine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receipt of blood transfusion(s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Endocrine abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of Grade 3-4 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Complete Remission Rate (CR + CRi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Clinicians Administered PTSD Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Global Longitudinal Strain ≥ 15%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Heavy Drinking Days Per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in IDS-C Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients with a positive B.pseudomallei culture result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction in 24 hour blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in left ventricle function (LVEF decrease ≥ 25%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Development of clinically overt rejection (heart failure, hemodynamic compromise)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dietary protein requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year Disease-free Survival (DFS)
Endpoint domain: Mortality/survival
Primary endpoint: Quality of ultrasound image
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Static bilateral grip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First occurrence of virologically confirmed symptomatic cases of COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: Change in Percentage of Parasites Detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change from baseline in insomnia score on Insomnia Severity Index
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change from baseline in depression and anxiety score on Hospital Depression and Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in participants' quality of life on the Functional Assessment of Cancer Therapy-General scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: changes in home diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: changes in home systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: changes in mean arterial blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Endometritis
Endpoint domain: Adverse events/effects
Primary endpoint: Vessel diameter changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung expansion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Subjects With Investigator Global Assessment (IGA) Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Excellent Overall Safety Score
Endpoint domain: Adverse events/effects
Primary endpoint: Local/radiographic control rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of MR techniques in detecting lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in BP to target values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in left ventricular hypertrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Perineal wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Dynamic Stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from progression for 3 years
Endpoint domain: Mortality/survival
Primary endpoint: Change on the Acne Scar Assessment Scale (ASAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in maximal oxygen consumption (VO2 max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exhaled nitric oxide (eNO) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Urinary Albumin to Creatinine Ratio (UACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Plasma concentrations of XueBiJing injection compounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uterine Tachysystole
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Post-treatment MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in Body Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total amount of high intensity signals (HITS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients treated with radiotherapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Insulin-stimulated Leg Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pain - Numeric Rating Scale Score at 1 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative acute pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response in symptoms of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pharmacokinetics of garlic oil macerate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of Signs and Symptoms of Infectious Keratitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Patient Ambulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical benefit of Step 2 Radiation dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: burden of atrial fibrillation
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Change in Cocaine Craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking symmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower incisors position changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who lost the evolutivity of their keratoconus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Periodontal Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local Inflammatory Markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: therapeutic treatment times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEF 25-75%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: breadth of protective activity of serum anti-FHbp antibody responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cardiovascular death or major adverse cardiovascular event
Endpoint domain: Mortality/survival
Primary endpoint: Resolution of Diarrhea (Less Than 3 Loose Stools/24 Hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Parasitological Response (no Detection of Cysts or Trophozoites on Microscopic Exam or Negative Antigen Test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in cordance value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of estradiol and testosterone in seminal plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Issue of testicular biopsy (sperm extraction positive or negative)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in DAT density in putamen and caudate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Upper Extremity Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in General Health Measures
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Functional Shoulder Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients who achieve SVR to DAA-based therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients who develop severe adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Degree of collateral estimated by Rentrop score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite event of all-cause mortality, non-fatal myocardial infarction, heart failure and repeat revascularization
Endpoint domain: Mortality/survival
Primary endpoint: 12 Month Treatment Free Remission
Endpoint domain: Mortality/survival
Primary endpoint: Heparinase Clot Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percent Change in Urine Protein/Creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Drug resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Serotype prevalence of S. pneumoniae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Highest numerical pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oxygen uptake kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of monoterpenes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diagnosis of pulmonary complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Antibody response to the first dose of hepatitis B vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in isokinetic knee extensor strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Complete Cell Cycle Arrest (CCCA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of RX108
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of fixed appliance orthodontic treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance walked during the test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Post-operative Nausea and Vomiting (PONV)
Endpoint domain: Adverse events/effects
Primary endpoint: Mortality or liver transplantation rate
Endpoint domain: Mortality/survival
Primary endpoint: Difference in 24 Hour Ambulatory Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Oxidative Stress as Measured by Urine Levels of F2-isoprostanes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Albuminuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Effect Size for Treated Items
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Treated Items
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival among patients with lung cancer
Endpoint domain: Mortality/survival
Primary endpoint: Motor threshold (MT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Probability of major molecular response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Invasive bacterial and fungal infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Area under the plasma concentration-time curve AUC0-t
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve AUC0-inf
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of colonoscopy preparation
Endpoint domain: Adverse events/effects
Primary endpoint: Doses delivered to the tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Doses delivered to organs at risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Degree of conversion of HER2 receptor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reproducibility of PET-CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma liraglutide concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dichotomous Hemostasis Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HCV Treatment Completion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Major Cardiovascular and/or Renal Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in fMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Minimal clinically important improvement of pain VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimal clinically important improvement of WOMAC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No knee surgery
Endpoint domain: Adverse events/effects
Primary endpoint: number of confirmed COVID-19 cases
Endpoint domain: Mortality/survival
Primary endpoint: Serum Bactericidal Titer ≥ 1:8 Against N.Meningitidis Serogroup C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients with NCI Grades 3 and/or 4 diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Cholesterol assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Triglycerides assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Disease Activity Score 28 (DAS 28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-hospital deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of days with substance use
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: BCVA (LogMAR) at Final Study Visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra individual variation of maternal thyroglobulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cord blood thyroglobulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Conversion rate from laparoscopic to open cholecystectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Area Under the Curve of tacrolimus pharmacokinetics (AUC0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in gait activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS (visual analogue scale) value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phrenic nerve stimulation measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: CR-POPF
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical success rate of apnea-hypopnea index (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: The scoring on the open wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Th1 type immune orientation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Using Evidence-based Template
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Efficacy superiority
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: HIV testing rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Clinically Significant Treatment Emergent Events
Endpoint domain: Adverse events/effects
Primary endpoint: All Cause Mortality at Day 28
Endpoint domain: Mortality/survival
Primary endpoint: Mean ApoB Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean TRL-C Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Total Production of ApoB48
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety and tolerability assessed by Dose Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability assessed by adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) of ASP1951
Endpoint domain: Adverse events/effects
Primary endpoint: Intensity of ADHD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Self reported Cognitive Performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in symptoms of Depression and Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Type of HIV-verifying medical institution
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Stent related lower urinary tract symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Evaluation of risk factors for colorectal polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Response Rate for Participants With Non-Hodgkin's Lymphoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Nasal Resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal Dryness and Discomfort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in health anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 24 Month Cumulative Success Rate
Endpoint domain: Mortality/survival
Primary endpoint: 24 Month Cumulative Stress Specific Success Rate
Endpoint domain: Mortality/survival
Primary endpoint: Patients' satisfaction with the games
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Kyphosis angle improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ocular cylinder and axis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of TEP-CT in identifying malignant lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced at Least One Grade 3+ Adverse Events Deemed at Least Possibly Related to Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: 4 point drop in modified VCSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee Laxity Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Inflammation control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fetal Thymus Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Reduction From Baseline in Log10 Plasma HCV RNA at Day 5 - HCV GT1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes